Accéder au contenu
Merck
Toutes les photos(1)

Documents

1368609

USP

Lisinopril

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H31O5N3 · 2H2O
Numéro CAS:
83915-83-7
Poids moléculaire :
441.52
Numéro MDL:
MFCD01698825
Code UNSPSC :
41116107
ID de substance PubChem :
329750250
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

lisinopril

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

Clé InChI

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Informations sur le gène

human ... ACE(1636)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lisinopril USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Lisinopril and Hydrochlorothiazide Tablets
  • Lisinopril Compounded Oral Suspension
  • Lisinopril Tablets

Actions biochimiques/physiologiques

Angiotensin converting enzyme (ACE) inhibitor.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

L0702000

Lisinopril dihydrate, European Pharmacopoeia (EP) Reference Standard

Y0001234

Lisinopril impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001701

Lisinopril for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001709

Lisinopril for system suitability A, European Pharmacopoeia (EP) Reference Standard

1368610

Lisinopril Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP695

Lisinopril dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2239

Lisinopril Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2495

Lisinopril Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360D,H373

Classification des risques

Repr. 1A - STOT RE 2

Organes cibles

Kidney

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Stephen J Bright et al.
Australasian journal on ageing, 34(1), 33-37 (2013-10-15)
The Alcohol-Related Problems Survey (ARPS) reliably classifies drinking as non-hazardous, hazardous or harmful using scoring algorithms that consider quantity and frequency of alcohol use alone and in combination with health conditions, medication-use and functional status. Because it has been developed
Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema.
M F Abdelmalek et al.
Digestive diseases and sciences, 42(4), 847-850 (1997-04-01)
K Simpson et al.
Drugs, 59(5), 1149-1167 (2000-06-14)
The ACE inhibitor lisinopril is a lysine derivative of enalaprilat, the active metabolite of enalapril. In patients with heart failure, maximum pharmacodynamic effects are produced 6 to 8 hours after administration of the drug and persist for 12 to 24
M C Nzerue
The Central African journal of medicine, 38(9), 391-392 (1992-09-01)
A case of angioedema induced by antihypertensive therapy with lisinopril is presented. The patient was a 70 year old black woman, with a history of hypertension for 15 years. The patient presented with acute onset of swelling involving the oro-facial
C Valenzuela et al.
General pharmacology, 25(5), 825-832 (1994-09-01)
1. The effects of lisinopril, an angiotensin-converting enzyme inhibitor, were studied on cardiac contractile force, action potential characteristics and membrane ionic currents. 2. In guinea-pig atria, lisinopril (0.001-1 microM) exerted a negative inotropic effect which was accompanied by a shortening
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique